CBIO Stock Price, Catalyst Biosciences Inc Quote, Chart

Market Summary

USD21.12-0.21

Delayed

-0.98%

CBIO Stock Price

View Fullscreen

CBIO RSI Chart

CBIO Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-23.82

Price/Sales (Trailing)

15.92

EV/EBITDA

-28.54

Price/Free Cashflow

68.19

CBIO Price/Sales (Trailing)

CBIO Profitability

EBT Margin

-57.08%

Return on Equity

-85.39%

Return on Assets

-62.13%

Free Cashflow Yield

1.47%

CBIO Fundamentals

CBIO Revenue

Revenue (TTM)

113.5M

Rev. Growth (Yr)

8.99%

Rev. Growth (Qtr)

4.3%

CBIO Earnings

Earnings (TTM)

-75.8M

Earnings Growth (Yr)

3.7K%

Earnings Growth (Qtr)

112.16%

Breaking Down CBIO Revenue

Last 7 days

-0.1%

Last 30 days

4.8%

Last 90 days

6.8%

Trailing 12 Months

-24.1%

How does CBIO drawdown profile look like?

CBIO Financial Health

Current Ratio

3.22

Debt/Equity

0

Debt/Cashflow

246.48

CBIO Investor Care

Dividend Yield

1.13%

Dividend/Share (TTM)

0.24

Shares Dilution (1Y)

126.46%

Diluted EPS (TTM)

-1.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	107.9M	0	0	113.5M
2022	54.8M	0	0	102.3M
2021	6.0M	5.5M	6.9M	7.3M
2020	9.0M	13.0M	17.0M	20.9M
2018	5.0M	0	0	0
2017	560.5K	562.5K	771.5K	1.0M
2016	1.2M	436.0K	436.0K	398.5K
2015	2.2M	2.8M	2.3M	1.7M
2014	845.5K	1.2M	1.5M	1.8M
2013	38.5M	4.9M	4.1M	523.0K
2012	81.5M	94.4M	76.2M	57.9M
2011	105.2M	105.0M	102.2M	97.6M
2010	0	45.3M	65.5M	85.7M
2009	0	0	0	25.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Catalyst Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 27, 2023	gni hong kong ltd	sold	-	-	-5,371,300	-
Aug 31, 2023	gni group ltd.	back to issuer	-	-	-6,266	-
Aug 31, 2023	lawlor augustine	back to issuer	-	-	-24.573	-
Aug 31, 2023	usman nassim	back to issuer	-	-	-8.456	president & ceo
Aug 31, 2023	usman nassim	back to issuer	-	-	-1.168	president & ceo
Aug 31, 2023	miller seline e.	back to issuer	-	-	-6.5	svp finance; interim cfo & pao
Aug 31, 2023	lawlor augustine	back to issuer	-	-	-24.215	-
Aug 31, 2023	hunt andrea	back to issuer	-	-	-28.228	-
Aug 31, 2023	usman nassim	back to issuer	-	-	-24.541	president & ceo
Aug 09, 2022	miller seline e.	bought	1,527	0.47	3,250	svp finance; interim cfo & pao

Which funds bought or sold CBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-1,696	-	-%
Mar 17, 2023	American Portfolios Advisors	unchanged	-	-275	108	-%
Aug 03, 2021	Johnson & Johnson Innovation - JJDC, Inc.	unchanged	-	-47,000	290,000	0.03%

Are Funds Buying or Selling CBIO?

Are funds buying CBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CBIO

No. of Funds

Unveiling Catalyst Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lytton laurence w	0%	0	SC 13G/A
Jan 24, 2024	gni group ltd.	85.34%	73,313,885	SC 13D/A
Nov 27, 2023	gni group ltd.	85.36%	73,313,885	SC 13D/A
Nov 01, 2023	gni group ltd.	85.36%	73,313,885	SC 13D/A
Oct 31, 2023	gni group ltd.	16.50%	6,266,521	SC 13D/A
Feb 14, 2023	nantahala capital management, llc	1.4%	438,055	SC 13G/A
Feb 14, 2023	orbimed advisors llc	0%	0	SC 13G/A
Feb 13, 2023	lytton laurence w	7.1%	2,667,333	SC 13G/A
Feb 13, 2023	renaissance technologies llc	3.14%	1,186,986	SC 13G/A
Jan 05, 2023	gni group ltd.	16.6%	6,266,521	SC 13D

Recent SEC filings of Catalyst Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 08, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 19, 2024	PRE 14A	PRE 14A
Apr 09, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Catalyst Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Catalyst Biosciences Inc News

Latest updates

Catalyst Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2
Revenue	4.3%	27,172,000	26,051,500	24,931,000	17,421,333	9,911,667	2,402,000	2,299,000	1,132,000	1,467,000	2,031,000	893,000	1,658,000	16,366,000	8,342,000	318,000	318,000	111,000	271,000	71,500	109,000	109,000
Costs and Expenses	-	19,101,000	-	18,267,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-89.5%	18,122,000	172,056,000	-178,000	40,274,000	15,495,000	22,753,000	27,528,000	21,046,000	23,905,000	20,872,000	16,993,000	19,019,000	21,434,000	-	-	-	-	-	-	-	-
S&GA Expenses	-76.1%	12,542,000	52,556,000	3,970,000	41,037,000	4,994,000	4,164,000	4,869,000	4,518,000	5,412,000	4,285,000	3,833,000	4,371,000	3,691,000	-	-	-	-	-	-	-	-
R&D Expenses	-	2,182,000	-	588,000	-	9,703,000	16,135,000	20,352,000	15,389,000	17,013,000	14,556,000	12,249,000	12,906,000	13,264,000	3,771,000	3,570,500	-	-	-	-	-	-
EBITDA Margin	16.9%	-0.55	-0.66	0.24	0.11	-1.57	-11.80	-2.72	-3.42	-3.12	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	328,000	-	184,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-70.0%	2,546,000	8,499,000	14,000	5,098,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	117.1%	12,481,000	-73,193,000	274,000	-22,800,000	-14,536,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	15.9%	-0.57	-0.68	0.22	0.09	-1.60	-12.05	-2.96	-3.72	-3.39	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	112.2%	9,935,000	-81,692,000	260,000	-27,898,000	-14,536,000	-20,329,000	-25,238,000	-19,928,000	-22,438,000	-18,907,000	-16,033,000	-17,248,000	-4,053,000	-	-	-	-	-	-	-	-
Net Income Margin	11.3%	-0.67	-0.75	0.18	0.04	-1.46	-12.05	-12.49	-14.00	-12.34	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-	2,653,000	-	-7,958,000	42,298,000	-12,050,000	-17,676,000	-22,092,000	-20,318,000	-24,551,000	-22,309,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.7%	122	117	10.00	12.00	19.00	85.00	31.00	83.00	40.00	56.00	79.00	102	119	95.00	112	124	111	99.00	92.00	101	112
Current Assets	9.6%	63.00	57.00	5.00	8.00	14.00	50.00	30.00	81.00	37.00	51.00	74.00	97.00	117	90.00	108	121	108	96.00	89.00	98.00	109
Cash Equivalents	-11.1%	30.00	34.00	2.00	7.00	8.00	25.00	23.00	75.00	35.00	44.00	59.00	74.00	83.00	30.00	25.00	59.00	70.00	15.00	23.00	17.00	25.00
Inventory	15.4%	5.00	4.00	-	-	-	6.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	1.2%	24.00	23.00	-	-	0.00	18.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-12.7%	33.00	38.00	6.00	7.00	11.00	13.00	2.00	4.00	13.00	15.00	18.00	17.00	15.00	19.00	18.00	15.00	13.00	30.00	11.00	8.00	6.00
Current Liabilities	-2.8%	19.00	20.00	2.00	3.00	7.00	12.00	2.00	4.00	13.00	14.00	17.00	16.00	14.00	18.00	17.00	14.00	12.00	29.00	9.00	6.00	4.00
Shareholder's Equity	536.4%	89.00	14.00	4.00	-	77.00	43.00	29.00	79.00	27.00	59.00	61.00	85.00	104	76.00	94.00	109	98.00	68.00	81.00	93.00	106
Retained Earnings	8.8%	-78.01	-85.50	-414	-413	-410	7.00	-370	-365	-417	-402	-382	-357	-337	-314	-295	-279	-262	-258	-244	-232	-218
Additional Paid-In Capital	95.4%	133	68.00	385	385	385	33.00	400	445	444	444	443	442	441	391	390	389	360	327	326	325	324
Accumulated Depreciation	9.5%	5.00	4.00	-	-	-	4.00	-	-	-	-	-	-	-	-	-	-	-	0.00	-	-	-
Shares Outstanding	11.5%	85.00	77.00	38.00	38.00	38.00	64.00	31.00	31.00	31.00	31.00	30.00	30.00	28.00	-	-	-	-	-	-	-	-
Minority Interest	7.9%	32.00	30.00	-	-	-	30.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	11.00	-	-	-	56.00	-	-	-	135	-	-	-	128	-	-	-	87.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-92.4%	2,884	37,804	-3,217	-2,471	-6,216	42,298	-7,277	-12,294	-12,050	-17,676	-21,600	-20,123	-24,356	-22,114	-13,008	-15,136	-4,790	-8,089	-9,100	-11,466	-14,958
Share Based Compensation	-99.8%	11.00	6,884	98.00	89.00	210	12,281	224	346	515	683	713	983	1,026	920	1,068	834	805	671	801	903	829
Cashflow From Investing	71.1%	-7,220	-24,966	-	4,795	411	-69,189	-	52,871	2,504	2,866	7,038	10,704	27,581	27,551	-21,267	-24,042	27,421	440	14,628	3,661	8,663
Cashflow From Financing	-95.7%	658	15,240	-1,478	-3,500	-7,762	-	-45,027	-	16.00	-	98.00	-4.00	49,459	-	-75.00	28,087	32,364	-	92.00	129	106
Dividend Payments	-	-	-	1,500	3,500	7,764	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CBIO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 27,172	$ 24,931
Operating expenses:
Cost of revenues	979	1,125
Selling and marketing	12,542	12,768
Research and development	2,182	2,635
General and administrative	3,398	1,739
Total operating expenses	19,101	18,267
Income from operations	8,071	6,664
Other income (expense), net:
Interest income, net	328	184
Other income	109	66
Change in fair value of warrant liability	4,288
Other expenses	(315)	(643)
Income before income taxes	12,481	6,271
Provision for income taxes	(2,546)	(2,054)
Net income	9,935	4,217
Net income attributable to noncontrolling interest	2,403	1,973
Net income attributable to common stockholders	$ 7,532	$ 2,244
Net income per share attributable to common stockholders, basic	$ 0.09	$ 0.04
Net income per share attributable to common stockholders, diluted	$ 0.03	$ 0.03
Weighted average shares used in calculating net income per share attributable to common stockholders, basic	83,265,879	63,588,119
Weighted average shares used in calculating net income per share attributable to common stockholders, diluted	102,594,197	78,921,366
Other comprehensive income:
Net income	$ 9,935	$ 4,217
Foreign currency translation adjustments	(141)	898
Comprehensive income	9,794	5,115
Net income attributable to noncontrolling interest	2,403	1,973
Foreign currency translation adjustments attributable to noncontrolling interest	(49)	395
Comprehensive income attributable to noncontrolling interest	2,354	2,368
Comprehensive income attributable to common stockholders	$ 7,440	$ 2,747

CBIO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 29,785	$ 33,509
Short-term bank deposits	7,567
Accounts and note receivables, net	15,458	15,552
Inventories, net	4,939	4,281
Prepaid assets	1,790	1,547
Other current assets	1,897	1,045
Total current assets	62,723	57,221
Property and equipment, net	23,564	23,288
Intangible assets, net	196	205
Right-of-use assets	359	489
Land use rights, net	1,480	1,493
Deferred tax assets	5,000	4,695
Long-term certificates of deposit	23,106	23,431
Other assets, noncurrent	802	995
Total assets	122,010	116,539
Current liabilities:
Accounts payable	330	355
Deferred revenue	35	39
Due to related parties	1,362	1,369
CVR excess closing cash payable	422	1,085
Accrued expenses and other current liabilities	10,767	11,935
Income tax payable	6,470	5,054
Operating lease liabilities, current	100	210
Total current liabilities	19,486	20,047
Operating lease liabilities, noncurrent	175	199
Deferred government grants	203	213
CVR derivative liability, noncurrent	4,780	4,722
Warrant liability, noncurrent	8,547	12,835
Other noncurrent liabilities	48	49
Total liabilities	33,239	38,065
Commitments and Contingencies (Note 12)
Stockholders' equity:
Common stock, $0.001 par value, 400,000,000 shares authorized; 85,423,246 shares and 76,595,616 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	85	77
Additional paid-in capital	133,199	68,179
Statutory reserve	3,098	3,098
Accumulated deficit	(78,006)	(85,538)
Accumulated other comprehensive loss	(1,736)	(1,644)
Total Gyre stockholders' equity (deficit)	56,640	(15,828)
Noncontrolling interest	32,131	29,777
Total equity	88,771	13,949
Total liabilities, convertible preferred stock, and equity	122,010	116,539
GC Biopharma Corp
Current assets:
Long-term receivable from GCBP	4,780	4,722
GNI
Current assets:
Other receivables from GNI	$ 1,287	1,287
Convertible Preferred Stock
Current liabilities:
Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively		$ 64,525

About Catalyst Biosciences Inc

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

CEO	Dr. Nassim Usman Ph.D.
WEBSITE	catalystbiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Catalyst Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Catalyst Biosciences Inc? What does CBIO stand for in stocks?

CBIO is the stock ticker symbol of Catalyst Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalyst Biosciences Inc (CBIO)?

As of Thu May 16 2024, market cap of Catalyst Biosciences Inc is 1.81 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CBIO stock?

You can check CBIO's fair value in chart for subscribers.

What is the fair value of CBIO stock?

You can check CBIO's fair value in chart for subscribers. The fair value of Catalyst Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Catalyst Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Catalyst Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CBIO is over valued or under valued. Whether Catalyst Biosciences Inc is cheap or expensive depends on the assumptions which impact Catalyst Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CBIO.

What is Catalyst Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, CBIO's PE ratio (Price to Earnings) is -23.82 and Price to Sales (PS) ratio is 15.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CBIO PE ratio will change depending on the future growth rate expectations of investors.